This article is written by Priya Chauhan, a law student at ICFAI University, Dehradun, with a keen interest in Intellectual Property Rights (IPR).
Introduction
One of the most important pillars of intellectual property law is the patent system. By giving inventors the exclusive right to use their creations for a set amount of time typically twenty years from the date of filing it is intended to promote creativity. In exchange, inventors must make their creations public, which advances technology and fosters new ideas. Finding a balance between compensating inventors for their work and guaranteeing that society eventually gains from greater access to new technology and medications is the main goal of patent law.
The practice of patent holders getting multiple patents on minor improvements of an existing product in order to prolong their monopoly beyond the original patent term is known as “patent evergreening”. New formulations, dosage forms, administration techniques, salts, polymorphs, or combinations that frequently offer very modest therapeutic improvement are examples of these changes. Whether such actions actually promote innovation or just postpone competition by keeping generic manufacturers out of the market is the main legal concern. This problem becomes especially important in the pharmaceutical sector because public health is directly impacted by the availability of reasonably priced medications. Legally speaking, patent evergreening poses issues with consumer welfare, competition law, abuse of patent rights, and the state’s constitutional duty to safeguard public health.
Understanding Patent Evergreening
The phrase “patent evergreening” is not specifically defined in patent statutes. Instead, it is an idea that has developed as a result of scholarly discussion and court rulings. In order to maintain market exclusivity after the original patent expires, a patent owner may file several follow-up patent applications pertaining to an invention that has previously been patented.
Evergreening in the pharmaceutical industry typically entails securing patents for small adjustments like:
- New crystalline forms (polymorphs)
- New salts or esters
- Modified dosage forms
- Controlled-release formulations
- New combinations of existing drugs
- New methods of treatment
- New indications for existing medicines
While some of these changes might in fact increase patient compliance, stability, or efficacy, others only serve to extend monopoly rights and have minimal therapeutic benefits.
The debate stems from the fact that patent law aims to recognize true inventions rather than insignificant advancements. Patents that are awarded too frequently for little changes hinder competition, keep drug costs high, and harm consumers.
Objectives behind Evergreening
Evergreening helps pharmaceutical businesses achieve a number of business goals.
It enables innovators to recoup significant investments in Research &Development. It frequently takes more than ten years of study, numerous clinical trials, and significant financial investment to develop a new medication. Companies contend that follow-up patents help offset the shorter duration of commercial exclusivity since regulatory approvals take up a large amount of the patent term.
Patient outcomes are frequently improved by small changes. Therapeutic efficacy and patient compliance may be increased by modified-release formulations, better stability, less adverse effects, and simpler delivery techniques. Rather than deterring additional advancements in currently available medications, longer patent protection promotes ongoing research.
However, detractors contend that these defenses are often employed to hide anti-competitive actions meant only to postpone generic entrance.
Legal framework in India
By safeguarding true innovation and prohibiting the misuse of patent rights, India has implemented one of the most balanced patent policies in the world.The Patents Act of 1970, as modified to conform to the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), is the controlling legislation. In 2005, India implemented product patents for pharmaceuticals along with measures to prevent patent evergreening.
Section 3(d) of the Patents Act, which prohibits some incremental inventions from becoming patentable, is the most important protection. According to Section 3(d), the simple discovery of a novel form of a known material is not patentable unless it improves the substance’s recognized efficacy. Salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixes, complexes, combinations, and derivatives are among the particular instances listed in the Explanation to Section 3(d) that call for evidence of increased efficacy.
This clause demonstrates India’s dedication to making sure that patents are only awarded for true technological breakthroughs rather than common changes.
Judicial Interpretation: Novartis AG v. Union of India
India’s patent jurisprudence on evergreening was revolutionized by the historic ruling in Novartis AG v. Union of India. The conflict pertained to Imatinib Mesylate; an anti-cancer medication sold under the brand name “Glivec.” The applicant claimed that the drug’s beta crystalline form had better physical characteristics and requested patent protection for it. Due to the applicant’s inability to prove improved medicinal efficacy, the Indian Patent Office denied the application under Section 3(d). The Supreme Court of India ultimately heard the case and upheld the denial. The Court noted that Section 3(d) could not be satisfied by enhanced bioavailability, better flow qualities, or improved storage characteristics alone. It was necessary for the applicant to prove improved therapeutic efficacy. The Court stressed that Section 3(d) was purposefully added by Parliament to avoid patent evergreening while yet adhering to TRIPS.
Genuine innovation must be rewarded by patent protection, not minor adjustments. Evidence of improved therapeutic efficacy is necessary for incremental inventions. Public health concerns and private rights must be balanced in patent law. Preventing evergreening promotes the availability of reasonably priced medications. Many people consider the Novartis ruling to be among the most significant patent rulings in the world.
International position
Patent evergreening is handled differently in various jurisdictions. The US has rather lax patentability regulations. If they meet the criterion of innovation and non-obviousness, secondary patents pertaining to formulations, therapeutic approaches, or changed dosage forms are often issued. As a result, pharmaceutical corporations frequently use large patent portfolios to protect market exclusivity. In a similar vein, incremental breakthroughs that satisfy the criteria of novelty, inventive step, and industrial applicability are eligible for patents from the European Patent Office. European law lacks a statutory equivalent of India’s Section 3(d), notwithstanding the existence of opposition processes. To avoid unwarranted monopolies, nations like Brazil and Argentina have implemented more stringent evaluation requirements for pharmaceutical patents. As a result, India’s strategy is regarded as distinct since its patent laws specifically include an anti-evergreening clause.
Arguments in support of evergreening
Advocates contend that patent evergreening is not inherently harmful.It is rare for scientific study to advance only through groundbreaking findings. A lot of technological developments happen gradually. Even if they don’t entail completely new chemical entities, advancements in medication delivery systems, stability, patient compliance, and manufacturing procedures could have a significant positive impact on healthcare.
Additionally, there are substantial commercial risks and extraordinarily high expenses associated with pharmaceutical innovation. Industry estimates state that years of study and billions of dollars are needed to bring a new medication to market. Without sufficient intellectual property protection, businesses might not be motivated to keep creating better treatments.
By facilitating advancements in dose, formulations, and targeted treatment approaches, secondary patents may help promote personalized medicine. Therefore, proponents argue that rather than being rejected outright, each incremental innovation should be evaluated independently.
Arguments Against Evergreening Patents
Opponents contend that evergreening often compromises the fundamental goals of patent law.
First, it prevents generic producers from joining the market long after the original patent has expired, so artificially extending monopolies.
Second, extended exclusivity raises the cost of medications dramatically, which has a negative impact on patients, hospitals, and public health systems.
Third, evergreening creates uncertainty in pharmaceutical markets by increasing litigation between innovator and generic companies.
Fourth, numerous overlapping patents produce what academics refer to as a “patent thicket,” which makes entering the market difficult both monetarily and legally.
Lastly, by rewarding regular changes rather than true technological advancements, patent evergreening may skew the patent system. Excessive monopolies may be in conflict with the State’s constitutional duty to advance public health and guarantee fair access to necessary medications.
Relationship with competition law
Lawful monopolies are granted by patent rights, although these monopolies are not unqualified. Under competition law, misuse of intellectual property rights may be investigated.
Competition authorities may look into such behavior as abuse of dominant position if patent holders deliberately use secondary patents only to keep out rivals who don’t truly innovate.
The goal of Indian competition law is to strike a balance between market competition and exclusive intellectual property rights. Intellectual property rights shouldn’t be used as tools for anti-competitive behavior, according to the Competition Commission of India.
Therefore, patent law and competition law work together to guarantee that innovation is rewarded without sacrificing the welfare of consumers.
Trips agreement and public health
The TRIPS Agreement gives member nations flexibility in determining patentability requirements while establishing basic standards for patent protection. Intellectual property protection shouldn’t stop member states from protecting public health, according to the Doha Declaration on the TRIPS Agreement and Public Health. Many people see India’s Section 3(d) as an example of this flexibility. It represents a reasonable policy decision meant to strike a balance between innovation and accessible healthcare, not a breach of international responsibilities.
As a result, India’s anti-evergreening policy has drawn a lot of attention from throughout the world as a model for poor nations looking to safeguard drug availability.
Challenges
Even if patent evergreening is successfully addressed by India’s legal system, there are still a number of real-world issues. To separate true innovation from minor changes, patent examiners need specific scientific knowledge. Additionally, courts must assess complicated pharmaceutical evidence while upholding judicial interpretation uniformity. Patent examination will be made more difficult by emerging technologies including biologics, biosimilars, gene treatments, artificial intelligence-driven medication development, and precision medicine.
Furthermore, poor nations are still under pressure to improve intellectual property protection as a result of international trade discussions. Therefore, India needs to strike the right balance between promoting innovation and ensuring that the general public has access to reasonably priced medications.
Conclusion
One of the most contentious topics in modern intellectual property law is patent evergreening. The patent system shouldn’t be used as a means of maintaining monopolies through minor changes, even when incremental innovation surely advances science. By enacting Section 3(d) of the Patents Act, which prohibits patents for novel versions of recognized substances unless they exhibit improved medicinal efficacy, India has taken a unique legal posture. In Novartis AG v. Union of India, the Supreme Court reiterated that patents need to honor true innovation rather than business tactics meant to stifle competition.The future of patent law ultimately depends on striking a careful balance between promoting innovation and defending the larger interests of society. A strong patent system should encourage genuine innovation while preventing intellectual property rights from obstructing access to necessary medications, fair competition, and affordable healthcare. A balanced legal framework may support both innovation and the public interest, as India’s developing jurisprudence shows.
